Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
Metrics to compare | XLO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipXLOPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.7x | −3.8x | −0.7x | |
PEG Ratio | −0.03 | 0.14 | 0.00 | |
Price/Book | 5.9x | 1.0x | 2.6x | |
Price / LTM Sales | 2.8x | 13.0x | 3.4x | |
Upside (Analyst Target) | 153.2% | 170.9% | 37.7% | |
Fair Value Upside | Unlock | 9.8% | 5.0% | Unlock |